Clinical parameters predictive for sphincter-preserving surgery and prognostic outcome in patients with locally advanced low rectal cancer.
Clinical parameters
Low rectal cancer
Predictive factors
Sphincter-preserving surgery
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
06 May 2020
06 May 2020
Historique:
received:
23
03
2020
accepted:
27
04
2020
entrez:
8
5
2020
pubmed:
8
5
2020
medline:
10
2
2021
Statut:
epublish
Résumé
Although controversial, there are data suggesting that clinical parameters can predict the probability of sphincter preserving procedures in rectal cancer. The purpose of this study was to investigate the association between clinical parameters and the sphincter-preserving surgery rate in patients who had undergone neoadjuvant combination therapy for advanced low rectal cancer. In this single center study, the charts of 540 patients with locally advanced rectal cancer who had been treated with induction chemotherapy-and/or neoadjuvant concomitant radiochemotherapy (nRCT) over an 11-year period were reviewed in order to identify patients with rectal cancer ≤6 cm from the anal verge, who had received the prescribed nRCT only. Univariate and multivariate analyses were used to identify pretreatment patient- and tumor associated parameters correlating with sphincter preservation. Survival rates were calculated using Kaplan-Meier analyses. Two hundred eighty of the 540 patients met the selection criteria. Of the 280 patients included in the study, 158 (56.4%) underwent sphincter-preserving surgery. One hundred sixty-four of 280 patients (58.6%) had a downsizing of the primary tumor (ypT < cT) and 39 (23.8%) of these showed a complete histopathological response (ypT0 ypN0). In univariate analysis, age prior to treatment, Karnofsky performance status, clinical T-size, relative lymphocyte value, CRP value, and interval between nRCT and surgery, were significantly associated with sphincter-preserving surgery. In multivariate analysis, age (hazard ratio (HR) = 1.05, CI95%: 1.02-1.09, p = 0.003), relative lymphocyte value (HR = 0.94, CI95%: 0.89-0.99, p = 0.029), and interval between nRCT and surgery (HR = 2.39, CI95%: 1.17-4.88, p = 0.016) remained as independent predictive parameters. These clinical parameters can be considered in the prognostication of sphincter-preserving surgery in case of low rectal adenocarcinoma. More future research is required in this area.
Sections du résumé
BACKGROUND
BACKGROUND
Although controversial, there are data suggesting that clinical parameters can predict the probability of sphincter preserving procedures in rectal cancer. The purpose of this study was to investigate the association between clinical parameters and the sphincter-preserving surgery rate in patients who had undergone neoadjuvant combination therapy for advanced low rectal cancer.
METHODS
METHODS
In this single center study, the charts of 540 patients with locally advanced rectal cancer who had been treated with induction chemotherapy-and/or neoadjuvant concomitant radiochemotherapy (nRCT) over an 11-year period were reviewed in order to identify patients with rectal cancer ≤6 cm from the anal verge, who had received the prescribed nRCT only. Univariate and multivariate analyses were used to identify pretreatment patient- and tumor associated parameters correlating with sphincter preservation. Survival rates were calculated using Kaplan-Meier analyses.
RESULTS
RESULTS
Two hundred eighty of the 540 patients met the selection criteria. Of the 280 patients included in the study, 158 (56.4%) underwent sphincter-preserving surgery. One hundred sixty-four of 280 patients (58.6%) had a downsizing of the primary tumor (ypT < cT) and 39 (23.8%) of these showed a complete histopathological response (ypT0 ypN0). In univariate analysis, age prior to treatment, Karnofsky performance status, clinical T-size, relative lymphocyte value, CRP value, and interval between nRCT and surgery, were significantly associated with sphincter-preserving surgery. In multivariate analysis, age (hazard ratio (HR) = 1.05, CI95%: 1.02-1.09, p = 0.003), relative lymphocyte value (HR = 0.94, CI95%: 0.89-0.99, p = 0.029), and interval between nRCT and surgery (HR = 2.39, CI95%: 1.17-4.88, p = 0.016) remained as independent predictive parameters.
CONCLUSIONS
CONCLUSIONS
These clinical parameters can be considered in the prognostication of sphincter-preserving surgery in case of low rectal adenocarcinoma. More future research is required in this area.
Identifiants
pubmed: 32375894
doi: 10.1186/s13014-020-01554-y
pii: 10.1186/s13014-020-01554-y
pmc: PMC7203844
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
99Références
Clin Colorectal Cancer. 2015 Dec;14(4):291-5
pubmed: 26433487
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):544-53
pubmed: 26723110
Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):483-91
pubmed: 21093174
Radiother Oncol. 2006 Jul;80(1):4-12
pubmed: 16730086
Eur J Surg Oncol. 2018 Aug;44(8):1241-1246
pubmed: 29739638
Int J Colorectal Dis. 2011 Jan;26(1):45-51
pubmed: 20809424
Eur J Cancer. 2009 May;45(7):1175-1183
pubmed: 19128956
Radiat Oncol. 2010 Jun 03;5:47
pubmed: 20525293
J Natl Cancer Inst. 2003 May 21;95(10):708-16
pubmed: 12759388
N Engl J Med. 2004 Oct 21;351(17):1731-40
pubmed: 15496622
World J Surg Oncol. 2015 Feb 07;13:30
pubmed: 25890185
Ann Surg Oncol. 2008 Oct;15(10):2661-7
pubmed: 18389322
J Natl Compr Canc Netw. 2018 Jul;16(7):874-901
pubmed: 30006429
Cancers (Basel). 2011 Apr 26;3(2):2176-94
pubmed: 24212803
Ann Surg Oncol. 2013 Dec;20(13):4169-82
pubmed: 24002536
Dis Colon Rectum. 2009 May;52(5):950-7
pubmed: 19502861
World J Surg. 2020 Jun;44(6):1975-1984
pubmed: 32020327
Br J Surg. 2012 May;99(5):603-12
pubmed: 22246846
Br J Surg. 2007 Oct;94(10):1285-92
pubmed: 17661309
Dis Colon Rectum. 2009 Jun;52(6):1065-71
pubmed: 19581848
Cancer. 2003 Jan 15;97(2):517-24
pubmed: 12518377
Cancer. 1983 Jul 1;52(1):126-30
pubmed: 6850535
World J Surg Oncol. 2017 Nov 22;15(1):205
pubmed: 29166925
Int Surg. 2014 Jul-Aug;99(4):330-7
pubmed: 25058761
Medicine (Baltimore). 2018 Sep;97(38):e11435
pubmed: 30235653
Int J Colorectal Dis. 2013 Apr;28(4):527-35
pubmed: 23080345
Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1075-80
pubmed: 11072165
Cochrane Database Syst Rev. 2013 Feb 28;(2):CD006041
pubmed: 23450565
Colorectal Dis. 2008 Jan;10(1):3-15; discussion 15-6
pubmed: 17477848
Yonsei Med J. 2015 Nov;56(6):1461-77
pubmed: 26446626
Ann Surg. 2008 Aug;248(2):243-51
pubmed: 18650634
BMC Cancer. 2011 Feb 10;11:64
pubmed: 21306650
Exp Ther Med. 2015 Aug;10(2):484-490
pubmed: 26622341
Radiother Oncol. 2019 Feb;131:52-59
pubmed: 30773187
Chirurg. 2015 Dec;86(12):1138-44
pubmed: 26347011
Dis Colon Rectum. 2005 Feb;48(2):195-202; discussion 202-4
pubmed: 15812583
Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1507-10
pubmed: 21940318
Ann Surg. 2009 Aug;250(2):260-7
pubmed: 19638922
J Clin Oncol. 1999 Aug;17(8):2396
pubmed: 10561302
Dis Colon Rectum. 2013 Jul;56(7):859-68
pubmed: 23739192
Br J Surg. 2012 Jul;99(7):918-28
pubmed: 22362002
Colorectal Dis. 2006 Jun;8(5):430-5
pubmed: 16684088